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miR-28-5p is an intragenic miRNA which is underexpressed in several tumor types showing a tumor suppressor (TS) activity.
Routinely, the known miR-28-5p targets are validated in speciﬁc tumor contexts but it is unclear whether these targets are also
being regulated in other tumor types. To this end, we adopted the miRNA pull out assay to capture the miR-28-5p targets in
DU-145 prostate cancer (PCa) cells. Firstly, we demonstrated that miR-28-5p acts as a TS-miRNA in PCa, aﬀecting cell
proliferation, survival, and apoptosis. Secondly, we evaluated the enrichment of the 10 validated miR-28-5p targets in the pull
out sample. We showed that E2F6, TEX-261, MAPK1, MPL, N4BP1, and RAP1B but not BAG1, OTUB1, MAD2L1, and p21
were signiﬁcantly enriched, suggesting that not all the miR-28-5p targets are regulated by this miRNA in PCa. We then veriﬁed
whether the miR-28-5p-interacting targets were regulated by this miRNA. We selected E2F6, the most enriched target in the
pull out sample, and demonstrated that miR-28-5p downregulated E2F6 at the protein level suggesting that our approach was
eﬀective. In general terms, these ﬁndings support the miRNA pull out assay as a useful method to identify context-speciﬁc
miRNA targets.
1. Introduction
It is well known that the deregulation of miRNA expres-
sion is one of the causes or contributory causes of cancer
development. miRNAs may act as tumor suppressors (TS),
oncogenes, or both depending on the tumor context [1].
miR-28-5p is an intragenic miRNA downregulated in several
tumor types, such as hepatocellular carcinoma [2], renal cell
carcinoma [3], natural killer/T-cell lymphoma [4], B-cell
lymphoma [5], colorectal cancer (CRC) [6], and CRC liver
metastasis [7, 8], although in some cases, an increased
expression level of miR-28-5p has been observed (ovarian,
esophageal, and cervical cancer) [9–11]. Most of the papers
regarding the role of miR-28-5p in tumors suggested a
prevalent tumor suppressor activity of this miRNA
in vitro [2, 3, 5, 6, 12]. Very recently, it has been demon-
strated that the miR-28-5p reexpression in xenograft models
of Burkitt (BL) and diﬀuse large B-cell lymphoma (DLBCL)
as well as in a BLmurine model blocked tumor growth, open-
ing the way to miR-28-5p-based replacement therapy as a
novel therapeutic strategy for these diseases [13].
The molecular targets through which miR-28-5p exerts
its anti- or proproliferative role are only partially known.
For example, miR-28-5p reduced cell growth and migration
in hepatocellular carcinoma [2] and in CRC [6] cells inhibit-
ing the expression of IGF-1, CCND1, and HOXB3 genes. In
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addition, miR-28-5p acted as a TS-miRNA in renal cell carci-
noma by directly repressing the expression of RAP1B [3] and
in B-cell lymphoma by directly inhibiting BAG1 expression,
a gene involved in the MAP-kinase pathway regulation [5].
To date, there are no data either on the role of miR-28-5p
in prostate cancer (PCa) or on the targets regulated by this
miRNA in PCa cells. In this work, we evaluated whether
the miR-28-5p targets validated in other types of tumors were
regulated in PCa cells using the miRNA pull out assay, a tech-
nique that allows the isolation of all the targets of a given
miRNA in speciﬁc biological contexts. We demonstrated that
miR-28-5p exerted TS activity in PCa cells and that not all
validated miR-28-5p targets are regulated by this miRNA in
the PCa context.
2. Materials and Methods
2.1. Cell and Culture Conditions. DU-145 and A-549 cells
were grown in RPMI Medium 1640 (EuroClone) whereas
PC-3 cells were grown in HAM’s medium (EuroClone) and
MCF-7 cells in DMEM low glucose (EuroClone). 10% FBS
(fetal bovine serum, EuroClone), 1% penicillin/streptomycin
(2mM, EuroClone), and 1% L-glutamine (2mM, Sigma-
Aldrich) were added to the medium. The cells were incubated
at 37°C in a humidiﬁed atmosphere containing 5% CO2.
2.2. Transfection. Transient transfections of double-stranded
miRNA mimics (miR-28a-5p) or negative control (miR-NC)
(GenePharma) in DU-145 cells were carried out using
Lipofectamine 2000 (Thermo Fisher): 1.5× 105 cells were
seeded in P30 dishes and after 48 hours, cells were transfected
with miRNA mimic using 10 μl of Lipofectamine accord-
ing to the protocol provided by the manufacturer. The
suspension of the transfected cells was used for cellular and
molecular assays.
2.3. Cell Proliferation. 1× 105 cells were seeded in a series of
30mm diameter dishes and grown for 96 hours. At 24-hour
intervals, cells were collected and counted.
2.4. Cell Cycle Analysis. Cell cycle analysis was performed
as follows: 5× 105 cells were ﬁxed with 95% cold ethanol
and labelled with 300 μl of 50 μl/ml propidium iodide
(Sigma-Aldrich) solution. After overnight incubation at
4°C, the cell cycle analysis was performed with Accuri™ C6
ﬂow cytometer (BD Biosciences). Using speciﬁc software
supplied with the instrument, the percentage of cells in each
phase of the cell cycle was determined considering the
parameters SSC-H/FL2-A.
2.5. Survival Assay. Survival was measured as follows: cells
were collected and seeded at cell density of 200 cells/60mm
diameter culture dish to allow colony formation. After
10–12 days, dishes were stained with 0.1% CV and the ratio
(number of colonies/number of seeded cells) was used to
calculate the fraction of surviving cells.
2.6. Apoptosis Assay. Apoptosis was measured as follows:
1× 106 cells were suspended in 300 μl Binding Buﬀer 1X
and left at room temperature for 15 minutes. Thereafter,
cell labelling was done according to the kit Annexin V-
FITC. Cells were then passed through ﬂow cytometer BD
Accuri C6 (BD Biosciences) and analyzed using FL3-H/
FL1-H parameters.
2.7. miRNA Pull Out Assay. The miRNA pull out assay
was performed as described in Rizzo et al. [14]. Brieﬂy,
DU-145 cells were transfected using Lipofectamine 2000
(Thermo Fisher) with 60 nM of either miR-28a-5p duplex
(ds-miR-28aCT) or a mix of 3′ biotin-tagged miR-28a-5p
8tU (nucleotide 8 was a thiouridine) and miR-28a-5p 18tU
duplexes (ds-miR-28aBIO). The day after transfection, cells
were irradiated with UV (365nm, 2 J/cm2) using Bio-Link
crosslinking (BLX) (Ambrose Lourmat) and total RNA
extracted adding TRIzol reagent (Thermo Fisher) directly
to adherent cells and following the instructions provided
by the manufacturer. 15 μg of RNA was incubated for
4 hours at 4°C with 100 μl of streptavidin-conjugated beads
(Streptavidin Sepharose High Performance, GE Healthcare),
and the RNA complexed with the beads recovered using the
Trizol protocol. We performed three biological replicates
obtaining three miR-28CT (miR-28 control) and three
miR-28BIO (miR-28) pull out samples.
2.8. Quantiﬁcation of miRNAs and mRNAs (qRT-PCR). Total
RNA was extracted from 1× 106 cells using the miRNeasy
mini kit following the manufacturer’s recommendations.
1 μg of total RNA was retrotranscribed using either the
miScript II RT kit (Qiagen) or the QuantiTect Reverse
Transcription Kit (Qiagen) for the miRNA or the mRNA
quantiﬁcation, respectively. The reverse transcription was
performed following the manufacturer’s instructions. miR-
NAs and the mRNAs were quantiﬁed with Rotor-Gene Q
2plex (Qiagen), using the miScript SYBR Green PCR Kit
(Qiagen) and the SsoAdvanced™ SYBR® Green Supermix
(Bio-Rad), respectively, according to the manufacturer
protocols. The relative quantiﬁcation was performed using
the Rotor-Gene Q software, normalizing to the internal con-
trols (U6, SNORD55, and SNORD110 for miRNA and
GAPDH, ACTB, and HPRT for mRNA). The relative miR-
28a-5p expression level in tumor cell lines was evaluated with
respect to the normal cell RNA (FirstChoice Human Total
RNA, Ambion). All reactions were performed in triplicate,
and the results are the mean of three biological replicates.
2.9. Western Blot Analysis. Proteins were extracted from cell
pellets using lysis buﬀer (1M Tris HCl pH8, Triton X-100
1%, and Na deoxycholate 0.25%) with the addition of PMSF
1mM. The proteins were then quantiﬁed colorimetrically
using the BioRad protein Assay Reagent (Bio-Rad). Absor-
bance was measured at 595nm with ChroMate microplate
reader (Awareness Technology). The proteins were separated
on polyacrylamide gels SDS-PAGE (10%, gel precast Mini-
PROTEAN® TGX Stain-Free™, Bio-Rad) and transferred to
0.2 μm nitrocellulose membranes by electro blotting using
the Trans-Blot Turbo Blotting System (Bio-Rad). The result-
ing blots were blocked with 5% nonfat dry milk solution in
TBST. Anti-GAPDH (Cell Signaling) (1 : 20000), anti-E2F6
(Santa Cruz Biotechnology) (1 : 500), and PARP-1 (Santa
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Cruz Biotechnology) (1 : 500) primary antibodies were used.
Incubation was performed overnight at 4°C, and bands were
revealed after incubation with the recommended secondary
antibody coupled to peroxidase using ECL (GE Healthcare).
Scanned images were quantiﬁed using ImageJ software and
normalized to GAPDH.
2.10. Statistical Analyses. Results are expressed as mean SD of
at least three independent experiments, and data are analyzed
using Student’s t-test (∗P < 0 05, ∗∗P < 0 01, ∗∗∗P < 0 001,
and ∗∗∗∗P < 0 0001).
3. Results
3.1. miR-28-5p Exerted a TS Activity in PCa Cells. To investi-
gate the role of miR-28-5p in PCa, we ﬁrst evaluated its
expression in two PCa cell lines (DU-145 and PC-3) com-
pared to normal cells (Figure 1(a)). We also evaluated the
expression of miR-28-5p in lung (A-549) and breast
(MCF-7) cancer cells, demonstrating that miR-28-5p was
markedly downregulated in all the analyzed cancer cell lines.
In order to test whether miR-28-5p behaves as a TS in
PCa cells, we ﬁrst measured cell proliferation of DU-145
and PC-3 cells after miR-28-5p reexpression. Data showed
a signiﬁcant inhibition of cell proliferation of both PCa cell
lines (Figures 1(b) and 1(c)). Similar results were obtained
when the miR-28-5p was transfected in breast and colon can-
cer cell lines (Figures 1(d) and 1(e)).
To further investigate the biological eﬀects of the miR-
28-5p in PCa, we checked the colony-forming ability (CFA)
and the cell cycle after miRNA reexpression in DU-145 cells.
Data showed that miR-28-5p reexpression resulted in both a
signiﬁcant reduction of CFA (Figure 2(a)) and a slight but
signiﬁcant increase of cells in G1 phase (Figure 2(b)), sug-
gesting that the proliferation was negatively aﬀected. Finally,
we demonstrated that the miR-28-5p reexpression increased
apoptosis in DU-145 cells (Figures 2(c) and 2(d)). Overall
data suggested that the miR-28-5p acts as a TS-miRNA in
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Figure 1: miR-28-5p expression and eﬀect on tumor cells. (a) Analysis of the miR-28-5p expression level with qRT-PCR in prostate
(PC-3 and DU-145), lung (A-549), and breast (MCF-7) cancer cell lines compared to the normal cell RNA. Cell proliferation of DU-145
(b), PC-3 (c), A-549 (d), and MCF-7 (e) cells at diﬀerent time points or at 96 hours after the miR-28-5p reexpression. ∗∗∗P < 0 001,
unpaired t-test.
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PCa, probably by regulating key pathways involved not only
in tumor cell proliferation but also in tumor cell survival.
3.2. Some Validated miR-28-5p Targets Interacted with miR-
28-5p in PCa. To investigate which targets were regulated
by miR-28-5p in PCa, we transfected this miRNA in
DU-145 cells and the miRNA pull out assay was performed
[14]. This technique allowed the capture and the isolation
of the miR-28-5p/target complexes using a biotinylated
version of miR-28-5p. We considered the miR-28-5p targets
deposited in miRTarBase (http://mirtarbase.mbc.nctu.edu.tw),
in particular, the ones validated with the luciferase reporter
assay (Table 1).
Using qRT-PCR, we checked the enrichment of these
targets in the pool of miR-28-5p-captured targets (miR-28
pull out sample) and found that RAP1B, N4BP1, MPL,
MAPK1, TEX-261, and E2F6 were enriched by more than
2-fold in the miR-28-5p pull out sample (Figure 3(a)). These
results suggested that not all the miR-28-5p-validated targets
interact and, as a consequence, may be regulated by miR-28-
5p in PCa cells.
To verify whether the enrichment of the selected targets
in the miR-28-5p pull out sample was indicative of the
miRNA regulatory function, we selected the most enriched
one, that is, E2F6, and determined its expression after the
miR-28-5p reexpression in DU-145 cells. We demonstrated
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Figure 2: Eﬀects of miR-28-5p reexpression on DU-145 cells. Cell survival (a) and cell cycle (b) in DU-145 cells after miR-28-5p reexpression.
Apoptosis analysis measured with both annexin assay (c) and western blot of PARP-1 and cleaved PARP-1 (d) in miR-28-5p-transfected
DU-145 cells. ∗∗P < 0 01 and ∗∗∗P < 0 001, unpaired t-test.
Table 1: miR-28-5p targets validated with gene reporter assay
according to miRTarBase.
miR-28-5p
target
Tumor type Reference
p21 Choriocarcinoma cells [15]
MPL Myeloproliferative neoplasms [16]
N4BP1
Myeloproliferative neoplasms/
ovarian cancer
[9]
OTUB1 Myeloproliferative neoplasms [16]
TEX-261 Myeloproliferative neoplasms [16]
MAPK1 Myeloproliferative neoplasms [16]
E2F6 Myeloproliferative neoplasms [16]
MAD2L1 B-cell lymphomas [5]
BAG1 B-cell lymphomas [5]
RAP1B
B-cell lymphomas/renal cell
carcinoma
[3, 5]
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that E2F6 was inhibited by miR-28-5p reexpression only at
the protein level (Figures 3(b) and 3(c)), indicating that
E2F6 was regulated by miR-28-5p in PCa.
4. Discussion
miRNAs are key inhibitors of gene expression that play a piv-
otal role in tumor development and progression aﬀecting
genes and pathways involved in all the hallmarks of cancer
[17, 18]. By regulating oncogenes or TS genes, they can act,
respectively, as a TS or oncogenes, although it is known that
the role of a speciﬁc miRNA in cancer is not absolute but
strongly related to the tumor context [1]. Therefore, it is
not surprising that miR-28-5p may act as an oncogene (e.g.,
[9]) or as a TS (e.g., [13]), even though in most tumors, it
showed an antiproliferative eﬀect. It is possible that, depend-
ing on the expression level of the targets or on the eﬀect of
regulators which interfere with miRISC binding or function,
not all the targets of a particular miRNA can be bound and
regulated by the miRNA in a speciﬁc context [19, 20].
In this work, performing the miR-28-5p pull out assay,
we have explored whether the known miR-28-5p targets,
deposited in miRTarBase and validated with at least the
luciferase reporter assay, interacted and were regulated by
miR-28-5p in PCa. Under this strategy was that, among all
miR-28-5p-validated targets, the ones that interact with
miR-28-5p in PCa have higher chance to be regulated by
the miRNA in this tumor. We ﬁrst evaluated the miR-28-
5p role in PCa, and we demonstrated for the ﬁrst time that
this miRNA is underexpressed in these cells and that its reex-
pression inhibited cell proliferation and survival. These data
led us to conclude that miR-28-5p acted as a TS-miRNA in
PCa. As it has been demonstrated that miR-28-5p negatively
regulated genes involved in tumor cell growth in lung [12] as
well as in colon rectal [6] cancer cells, we checked the expres-
sion level and the eﬀects of miR-28-5p in lung and colon
cancer cell lines as a positive control.
Using the miRNA pull out assay, we found that not all
the validated miR-28-5p targets were enriched in the miR-28
pull out sample. Among the enriched targets that are more
strongly associated with cancer (i.e., RAP1B, N4BP1,
MAPK1, and E2F6), almost all are protumoral. Indeed, both
MAPK1 and RAP1B, a Ras-related small GTP-binding pro-
tein that acts as GTPase in several signaling cascades, are
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Figure 3: miR-28-5p target validation. (a) miR-28-5p-validated target enrichment quantiﬁed by qRT-PCR in miR-28-5p pull out sample
compared to miR-28-5p control pull out sample (CT). E2F6 mRNA (b) and protein (c) quantiﬁcation in DU-145 cells transfected with
miR-28-5p or miR-NC. ∗P < 0 05, ∗∗P < 0 01, ∗∗∗P < 0 001, and ∗∗∗∗P < 0 0001 unpaired t-test.
5International Journal of Genomics
proproliferative proteins involved as oncogenes in the
development and progression of several tumor types (e.g.,
[21, 22]). In particular, it has been demonstrated that miR-
28-5p suppressed cell proliferation and migration by directly
inhibiting RAP1B in renal cell carcinoma [22]. These obser-
vations are consistent with a possible regulation by miR-28-
5p, suggesting the utility of our approach to identify
context-speciﬁc miRNA targets. In the same way, it has been
reported that when PCa evolves from a benign to more
aggressive stage, it becomes resistant to apoptosis due to the
increased expression of antiapoptotic proteins [23] such as
E2F6 [24]. Indeed, we demonstrated that E2F6, the most
enriched target in the miR-28-5p pull out sample, was regu-
lated by miR-28-5p at the posttranscriptional level. We can
speculate that the target enrichment level in the miRNA pull
out sample might facilitate the identiﬁcation of the targets
aﬀected by the regulation of the miRNA. In addition, we also
showed that the miR-28-5p reexpression induced apoptosis
in DU-145 cells. Given that DU-145 cells (androgen inde-
pendent PCa cell line) are an advanced PCa in vitro model,
miR-28-5p reexpression may be taken into consideration as
a novel therapeutic approach for PCa at this stage. Further-
more, we demonstrated that E2F6 is regulated by miR-28-
5p in DU-145 cells; thus, it is conceivable that E2F6 could
be one of the mediators of the apoptosis induced by miR-
28-5p reexpression.
In conclusion, in this work, we demonstrated that the
capture of the targets that interact with a given miRNA in a
speciﬁc tumor is a suitable approach to identify the subset
of targets that have a higher probability of being regulated
by that miRNA in the context under evaluation. In the future,
the identiﬁcation of all the miR-28-5p targets (miR-28-5p
targetome) could help to decipher the genes and pathways
aﬀected by the regulation of this miRNA in PCa.
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